N-terminal of SARS-CoV-2/COVID-19 Nucleocapsid protein was used as the immunogen for this antibody.
The structural nucleocapsid (N) protein of nCoV/SARS-CoV-2/COVID-19 is a predicted 46 kDa phosphoprotein having 419 amino acid residues. A short Serine rich stretch and a recognized nuclear localization signal are the unique features of the nucleocapsid protein of nCoV/SARS-CoV-2/COVID-19, which seems to have a little homology with the proteins of other members of this large corona virus family. These features also suggest the involvement of nucleocapsid protein of nCoV/SARS-CoV-2/COVID-19 in different stages of viral lifecycle. The protein has multifaceted activities including packing of the nCoV/SARS-CoV-2/COVID-19 viral genome into a helical ribonucleocapsid (RNP) and playing an important role in viral self-assembly causing nCoV/SARS-CoV-2/COVID-19. The nucleocapsid protein of nCoV/SARS-CoV-2/COVID-19 also forms dimer in the cell by self-association with the help of interactive C terminal domain.
Clonality:
Polyclonal
Purity:
Protein A Chromatography
Form:
Purified
Target:
SARS-CoV2 N-Term Nucleocapsid
Application Dilute:
Recommended dilutions: WB: 0.1-0.5 µg/ml. However, this need to be optimized based on the research applications.
Figure-2: Western Blot analysis of SARS-CoV2 N-Term Nucleocapsid antibody: Anti- SARS-CoV2 N-Term Nucleocapsid antibody (SARS-CoV-2) was used at 0.5 µg/ml on recombinant Nucleocapsid Protein (21-1003).
Figure-1: Western Blot analysis of SARS-CoV-2 Nucleocapsid Protein: Anti-SARS-CoV-2 Nucleocapsid Protein (11-2007) was used at 2 µg/ml on (1) SARS-CoV-2 virus infected Vero Cell lysate and (2) Mock infected lysate.
* VAT and and shipping costs not included. Errors and price changes excepted
